Capsida Biotherapeutics, a Newbury Park-based startup that recently raised $140 million in Series A funding, is partnering with a high-profile biotech company to develop treatment for Lou Gehrig’s disease (amyotrophic lateral sclerosis) and Friedreich’s ataxia, another neurodegenerative disease.
Capsida will work with the Swiss firm CRISPR Therapeutics to research, develop, manufacture and commercialize “in vivo” gene-edited therapies for the conditions, the companies said in a statement released June 15. Capsida is developing a platform to target specific tissue types and limit the impact on tissues and cell types not relevant to the target disease, potentially allowing for improved efficacy and safety.
CRISPR, a publicly traded company valued at around $9 billion, will lead the Friedreich’s ataxia program, and Capsida will lead the ALS program. Should their efforts be successful, the companies would equally share all research, development and commercialization costs and profits worldwide related to the collaboration product, according to the release.
As part of the collaboration, Capsida will be responsible for process development and clinical manufacture and have the option to manufacture commercial products generated under the agreement.
The company, backed by Westlake-based venture capitalist Beth Seidenberg, recently expanded into a second space in the 1200 block of Rancho Conejo Boulevard. It employs around 100 locally people.